Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Plus Raltitrexed Maintenance in Advanced Colorectal Cancer
NCT04241731Phase 2Unknown
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed and KL-140 in colorectal cancer (CRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Time from the beginning of first-line treatment until disease progression at 24 months and Time from the beginning of maintenance treatment until disease progression at 24 months. Status: unknown.
02
Drugs
raltitrexedKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04241731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241731.